LifeMD, Inc. · NASDAQ:LFMD

LifeMD — Investor Presentation (March 2024)

22 slides from LifeMD's investor presentation, March 2024

  1. Slide 1: Investor Presentation March 2024

    Investor Presentation March 2024 NASDAQ: LFMD

  2. Slide 2: Important cautions regarding forward-looking statements

    2 Important cautions regarding forward-looking statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Priva

  3. Slide 3: Building the leading platform for comprehensive virtual healthcare

    Building the leading platform for comprehensive virtual healthcare 850,000 Virtual Consults Conducted End-to-end, compliance-first platform for direct-to- consumer virtual primary care Early-mover advantage and partnership strategy create a 215,000 Active Patients deep competitive moat Affiliated 50

  4. Slide 4: Investment highlights

    Investment highlights Proven ability to operate at scale within large and growing addressable markets thanks to robust infrastructure Differentiated, end-to-end technology platform and affiliated medical group supporting complex virtual primary care needs of 800-1,000 new patients per day Significan

  5. Slide 5: Telehealth can solve many of the biggest problems facing the U.S. healthcare system

    5 Telehealth can solve many of the biggest problems facing the U.S. healthcare system Need Solution 1/3 of Americans don’t have a primary care doctor, At LifeMD, the median time from scheduling to the Timeliness and the average wait time to see a family doctor is first provider appointment is only 2

  6. Slide 6: A $170 billion total addressable market in the U.S.

    6 A $170 billion total addressable market in the U.S. LifeMD’s virtual care platform is addressing unmet needs in primary care and specialized healthcare. Male and Female Sexual Health Insomnia U.S. Primary Care Market Weight Management Integrative Health & Wellness $170B Diabetes Management Hormone

  7. Slide 7: LifeMD has built an end-to-end platform for comprehensive virtual healthcare

    7 LifeMD has built an end-to-end platform for comprehensive virtual healthcare Patient Acquisition Diagnostics Internal creative, online/offline media Integrations with Quest & LabCorp buying, SEO, and CRM platform and in-home collection Business Intelligence Telehealth Data & analytics platform to

  8. Slide 8: Technology designed to provide best-in-class experience and care for all stakeholders

    8 Technology designed to provide Best-in-class experience and care for all stakeholders For Patients For Providers For Partners For Industry Patients benefit from an intuitive Streamlined workflow optimization Flexible partnerships with unique Life sciences companies who partner virtual care platfor

  9. Slide 9: Our affiliated medical group, staffed by full-time providers, is central to our success

    Our affiliated medical group, staffed by full-time providers, is central to our success 99% 850K 200+ 4.9/5 Of consults start on Consults completed Different conditions Average physician time* LifeMD treats rating Dr. Gupta 98% 50 LifeMD Affiliated Provider “I love what I do because I Patients satis

  10. Slide 10: Our success is driven by three core pillars

    10 Our success is driven by three core pillars DTC Telemedicine Virtual Primary Care B2B Solutions Subscription-based treatment Services include primary care, Digital front-door strategies for + Rx Offerings urgent care, and chronic healthcare product companies condition management Established, whol

  11. Slide 11: Our track record of strategic focus and growth

    Our track record of strategic focus and growth JUNE JUNE NOVEMBER APRIL Acquired cloud – Commenced tech build Launched Launched GLP-1 based telehealth for LifeMD Virtual Primary VPC Platform offering on VPC technology platform Care (VPC) platform platform FEBRUARY AUGUST December 2023 DECEMBER Chang

  12. Slide 12: Clear strategy focused on scaling high-value revenue streams

    12 Clear strategy focused on scaling high-value revenue streams Key Priorities Goals Virtual Primary Care Continue to scale weight management/GLP-1 offering High Value Revenue Streams With Long-Term Brand Equity Launch cardiovascular health and hormone therapy offerings Launch commercial health insu

  13. Slide 13: WorkSimpli Software is rapidly growing and highly profitable

    WorkSimpli Software is rapidly growing and highly profitable Rapidly growing, global provider of Workplace and document Software-as-a-Service offerings to consumers and small businesses specializing in the pdf, resume/ HR, digital signature and forms markets Over 158,000 subscribers with platform av

  14. Slide 14: Our management team has deep experience leading innovative healthcare organizations

    14 Our management team has deep experience leading innovative healthcare organizations Justin Schreiber Marc Benathen Stefan Galluppi Jessica Friedeman Chief Executive Chief Financial Officer Chief Innovation Chief Marketing Officer Officer & Chairman Officer Eric Yecies Dennis Wijnker Nick Alvarez

  15. Slide 15: Our businesses have experienced rapid, consecutive YoY growth

    $200M Our businesses have experienced rapid, consecutive YoY Growth $65M $152M $200M $119M $54M 2024E Revenue Forecast $93M $36M 31% $25M $135M Forecast 2024 Growth Rate Versus 2023 $98M $83M $37M $68M $7M 850K+ $13M $2M $30M Patients & Customers $11M To-Date 2019A 2020A 2021A 2022A 2023A 2024E 198%

  16. Slide 16: Rapid growth in profitability after achieving adjusted EBITDA profit in Q4 '22

    16 Rapid growth in profitability after achieving adjusted EBITDA profit in Q4 ‘22 Annual consolidated adjusted EBITDA ($ millions) $20M $12M 2023A 2024E $(15)M ($38)M 2022A 2021A Note: Consolidated adjusted EBITDA includes Telehealth and WorkSimpli results. 2024 Forecast is based on the midpoint of

  17. Slide 17: Rapidly expanding gross margins and increasing leverage on marketing spend

    17 Rapidly expanding gross margins and increasing leverage on marketing spend driving continued growth in profitability Consolidated Gross Margin % Marketing Expenses as % of Net Revenue 90% 125% 44 89% 41 100% Net Revenue ($ Millions) 88% 38 51% 87% 72% 62% 35 75% 50% 54% 86% 55% 32 85% 45% 50% 29

  18. Slide 18: 2024 guidance reflects substantial increases in both revenue and profitability

    2024 guidance reflects substantial increases in both revenue and profitability FY 2024 GUIDANCE FY 2023 ACTUAL DELTA Telehealth Revenue $135 million $98 million +38% WorkSimpli Revenue $65 million $54 million +20% Consolidated Revenue $200 million $152 million +31% Consolidated Adj. EBITDA $20 milli

  19. Slide 19: In summary

    19 In summary Significant presence within established and growing addressable markets Proprietary technology platform differentiated by leading 50-state, affiliated physician network High margin products/services generating 85%+ consolidated gross margins Powerful telehealth infrastructure enabling

  20. Slide 20: Appendix

    20 Appendix LifemD"

  21. Slide 21: Reconciliation of GAAP Net Loss to Adjusted EBITDA

    Reconciliation of GAAP Net Loss to Adjusted EBITDA (in whole numbers, unaudited)

  22. Slide 22: Company Contact

    Company Contact Marc Benathen marc@lifemd.com Media Contact press@lifemd.com

LifeMD — Investor Presentation (March 2024) on 6ix